Curated news and analysis on clinical trials, drug approvals, and medical research.
Eli Lilly builds $1.5B stockpile for oral obesity drug orforglipron; study shows GLP-1s cut cancer risk; logistics firms invest in cold chain; and amylin drug race heats up with $19B in deals.
A real-world study in Galicia showed nirsevimab reduced RSV-related hospitalizations by 85.9% in the first season and 55.3% in the second. The RSV prevention market is expanding to cover high-risk children, with Beyfortus the only antibody approved for second-season use. The FDA has cited Sanofi for misleading promotional claims about the product.
The FDA has refused to file Moderna's flu vaccine candidate mRNA-1010. The company will push forward outside the U.S. and pause its combination flu vaccine, while expressing disappointment over the decision's regulatory implications.
Institutional investors disclosed major changes to their AbbVie holdings as the stock hovers near record levels. AbbVie maintains a Moderate Buy analyst consensus with a $268.10 price target, buoyed by strong quarterly earnings and a newly declared dividend.
St. Jude Children’s Research Hospital experts are creating evidence-informed consensus guidelines covering brain tumor diagnosis, pharmacogenomics, survivorship care, and rare blood disorders. Their work helps clinicians translate the latest data into improved diagnosis, treatment, and follow-up care globally.
Flow chemistry, laboratory mixer, and industrial extruder markets are projected to grow significantly through 2035, driven by pharmaceutical continuous manufacturing, high R&D funding, and sustainability trends. Flow chemistry is expected to reach $12 billion, while laboratory mixers could hit $29.6 billion. Key players include Merck KGaA, BASF, and Lonza.
The Biotechnology Sciences and Engineering Building at UTSA will experience three planned utility outages: a steam outage on Feb. 19, a water outage on May 23, and a multi-day steam outage from July 31 to Aug. 2. These outages are necessary for repairs and maintenance, temporarily affecting lab equipment and water access.
A phase 3 trial of azacitidine and chidamide plus CHOP in untreated PTCL showed a significant overall survival improvement but no significant gains in response rate or progression-free survival. The study suggests molecular profiling could guide future therapies.
Celltrion released new post-hoc analysis from its phase 3 trial of Remsima SC in IBD patients at the ECCO 2026 congress. The data showed rapid clinical response after treatment gaps and maintained efficacy over 102 weeks. The company also highlighted its unique offering of infliximab in three formulations.
Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.
The White House issued a report urging federal agencies to fund scientific research beyond university labs, favoring individual researchers and multiyear grants. Critics call the plan a rhetorical move that could undermine the existing research enterprise, while the administration frames it as necessary for complex, large-team science.
Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.
Eli Lilly will file its triple-agonist obesity drug retatrutide in early 2027 via a Biologics License Application, seeking stronger market protections. Positive Phase 3 results showed up to 22.6% weight loss, while cardiovascular safety data raised some questions.
A sustained telehealth program combining counseling and nicotine replacement therapy boosted 6-month smoking abstinence to 28.4% vs. 14.7% with quitline referral, a national trial found. The intervention was well-engaged and satisfied patients.
Lonza announced a licensing agreement with Engitix to develop ADCs using its technology platform, alongside an expansion of its Advanced Synthesis offering that integrates GlycoConnect, HydraSpace, and toxSYN technologies. The Oss site has been upgraded to support bioconjugate R&D and pilot toxicology supply.
Stony Brook University and SWFT Labs expanded a partnership to commercialize cellulose nanomaterials as plastic alternatives, advancing the 'Silicon Island' vision for Long Island as a tech hub. The effort is backed by state quantum and biotech investments.
Researchers have discovered a novel broadly neutralizing antibody, 007, that targets the HIV-1 V3 glycan site in a glycan-independent manner, overcoming escape mechanisms. The antibody demonstrated robust neutralization of resistant viral strains, synergized with existing antibodies in humanized mice, and is now advancing preclinically with Vir Biotechnology. This breakthrough may guide next-generation vaccine strategies amid ongoing efforts to induce broadly neutralizing antibodies through novel immunogen designs.
Tortugas Neuroscience and Korsana Biosciences emerged with significant funding to advance clinical-stage pipelines targeting neurological and neurodegenerative diseases. Tortugas raised $106 million, while Korsana secured $175 million to develop therapies for conditions including Alzheimer's, schizophrenia, and epilepsy.
Governments in the UK, Australia, and New York City are overhauling planning rules to fast-track major infrastructure projects, from clean energy and transport to Olympic venues and street safety improvements. The UK has confirmed reforms to cut pre-application time by up to 12 months and save £1 billion, while Queensland is streamlining approvals for Brisbane 2032 Games projects, and New York City has proposed ballot measures to accelerate permits and contracts.
A Cochrane review finds exercise for hip osteoarthritis reduces pain by 7 points on a 100-point scale, below the 12-point threshold for noticeable benefit. A survey shows 76% of physical therapy patients skip home exercises, citing forgetfulness and time constraints. A study reports only 22% of stroke and brain injury survivors receive intensive inpatient rehab, with disparities by race, insurance, and income.
